An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Key General Inclusion Criteria

   - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

   - Life expectancy >/= 12 weeks

   - Adequate hematologic and end-organ function

   - For participants receiving therapeutic anticoagulation: stable anticoagulant regimen

   - Negative serum pregnancy test for women of childbearing potential

   - Histologically confirmed locally advanced, recurrent, or metastatic incurable solid
   tumor malignancy

   - Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

   - Availability of representative tumor specimens

Key General Exclusion Criteria

   - Pregnant or breastfeeding, or intending to become pregnant during the study

   - Significant cardiovascular disease

   - Current treatment with medications that prolong the QT interval

   - Known clinically significant liver disease

   - Poorly controlled Type 2 diabetes mellitus

   - Symptomatic, untreated, or actively progressing CNS metastases

   - History of leptomeningeal disease

   - History of malignancy other than disease under study within 3 years prior to screening

   - Active or history of autoimmune disease or immune deficiency

   - Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus
   infection

   - Positive for HIV infection

   - Prior allogeneic stem cell or solid organ transplantation